When J&J reported second-quarter results, exceptional performance from younger products in the pipeline encouraged the company to raise its full-year outlook. Unfortunately, investors weren't able to focus on the numbers thanks to mounting legal expenses.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,